Evidence map›Paper›PMID 37561208›Full record

ArticleJournal of cancer research and clinical oncology2023

Thymidine kinase 1 appears to be a marker for the prognosis of hepatocellular carcinoma based on a large-scale, multicenter study.

Yi Jiang, Lu Guo, Lei Han, Han Li, Changlun Li, Lianbin Wen, Yanqiong Song, Zhaoyang Wang, Pan Wang, Qulian Guo and 11 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Journal of cancer research and clinical oncology, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 11 papers.

0numbers the graph read from it
0cells of the map it votes in
11citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

11 citing papers in PubMed.

  1. Trial
  2. Article
  3. Article
  4. Review
  5. Article
  6. Article
  7. Lasso-Cox interpretable model of AFP-negative hepatocellular carcinoma.Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico · 2025
    Article
  8. Review
  9. Article
  10. Article
  11. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

21 authors.

Yi Jiang *Department of Oncology, The Affiliated Hospital of Southwest Medical University, Luzhou, 646000, China.
Lu Guo *Department of Ophthalmology, The Affiliated Hospital of Southwest Medical University, Luzhou, 646000, China.
Lei Han *Department of Oncology, Affiliated Hospital of Jining Medical University, Jining, 272000, China.
Han Li *Department of Oncology, The Affiliated Hospital of Southwest Medical University, Luzhou, 646000, China.
Changlun LiDepartment of Oncology, Affiliated Hospital of Jining Medical University, Jining, 272000, China.
Lianbin WenDepartment of Geriatric Cardiology, Sichuan Academy of Medical Sciences and Sichuan Provincial People's Hospital, Chengdu, 610072, China.
Yanqiong SongDepartment of Radiotherapy, Sichuan Cancer Hospital and Institute, Sichuan Cancer Center, School of Medicine, University of Electronic Science and Technology of China, Chengdu, 610042, China.
Zhaoyang WangDepartment of Medical Imaging, Southwest Medical University, Luzhou, 646000, China.
Pan WangClinical Skills Center, The Affiliated Hospital of Southwest Medical University, Luzhou, 646000, China.
Qulian GuoDepartment of Paediatrics, The Affiliated Hospital of Southwest Medical University, Luzhou, 646000, China.
Wenxi ZhaoClinical Medical College, Southwest Medical University, Luzhou, 646000, China.
Mengxiang LiuSchool of Humanities and Management, Southwest Medical University, Luzhou, 646000, China.
Jiali ChenDepartment of Oncology, The Affiliated Hospital of Southwest Medical University, Luzhou, 646000, China.
Zhenying WuDepartment of Oncology, The Affiliated Hospital of Southwest Medical University, Luzhou, 646000, China.
Yushan YanDepartment of Oncology, The Affiliated Hospital of Southwest Medical University, Luzhou, 646000, China.
Ke XuDepartment of Oncology, Chongqing General Hospital, Chongqing, 401147, China.
Tao GuDepartment of Oncology, The Affiliated Hospital of Southwest Medical University, Luzhou, 646000, China.
Xue WuDepartment of Oncology, The Affiliated Hospital of Southwest Medical University, Luzhou, 646000, China.
Kun HeClinical Research Institute, The Affiliated Hospital of Southwest Medical University, Luzhou, 646000, China.
Ke SuDepartment of Oncology, The Affiliated Hospital of Southwest Medical University, Luzhou, 646000, China. sukedsg123@163.com.
Yunwei HanDepartment of Oncology, The Affiliated Hospital of Southwest Medical University, Luzhou, 646000, China. Lanpaoxiansheng@126.com.

Funding

Qulian Guo 2022YFS0622
6 · The paper itself

Abstract

introductionThe aim of this study was to investigate the role of thymidine kinase 1 (TK1) levels in hepatocellular carcinoma (HCC) prognosis and to develop a nomogram for predicting HCC prognosis.

methodIn this study, 1066 HCC patients were enrolled between August 2018 and April 2022. TK1 levels were measured within one week before enrollment, and the relationship with HCC prognosis was evaluated. Next, all patients were randomly assigned to the training set (70%, n = 746) and the validation set (30%, n = 320). We used multivariate Cox analysis to find independent prognostic factors in the training set to construct a nomogram. The predictive power of the nomogram was assessed using receiver operating characteristic (ROC) curves, calibration curves, and decision curve analysis (DCA). The optimal critical value of TK1 was determined as 2.35 U/L using X-tile software.

resultBefore and after propensity score matching (PSM), the median overall survival (mOS) of the low-TK1 group (< 2.35 U/L) remained significantly longer than that of the high-TK1 group (≥ 2.35 U/L) (48.1 vs 16.5 months, p < 0.001; 75.7 vs 19.8 months, p = 0.001). Moreover, multivariate Cox analysis showed that the low TK1 level was an independent positive prognostic indicator. Additionally, the area under the ROC curve for predicting the 1-year, 2-year, and 3-year survival rates was 0.770, 0.758, and 0.805, respectively.

conclusionsTK1 could serve as a prognostic marker for HCC. In addition, the nomogram showed good predictive capability for HCC prognosis.

Indexed as

Hepatocellular carcinomaNomogramPrognostic factorPrognostic markerThymidine kinase 1Transcatheter arterial chemoembolization

Identifiers

PMID37561208
PMCPMC11797990

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.